National Institute of Neurological Disorders and Stroke (NINDS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).
National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.
National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.
Top-decile sponsor footprint
National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
567 total, page 2 of 12
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
NCT04742400
Clinical Laboratory Evaluation of Chronic Autonomic Failure
NCT03648905
Deep Brain Stimulation Surgery for Focal Hand Dystonia
NCT02911103
Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy
NCT02362438
A Prospective Natural History Study of Patients With Syringomyelia
NCT01150708
Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
NCT00005902
Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD
NCT07613112
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
NCT07388550
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
NCT02522611
Procedural Motor Memory in Long COVID-19
NCT05746624
Task-dependent Effects of TMS on the Neural Biomarkers of Episodic Memory
NCT04694131
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
NCT04781309
Layer-specific Contribution to Consolidation of Skill Learning in the Primary Motor Cortex
NCT04431011
Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)
NCT04584346
Study of Volition: Behavioral Analysis and Clinical Neurophysiological Analysis
NCT04344470
Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)
NCT04565080
An Observational Study of Neurologic Function After COVID-19 Infection
NCT04564287
Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)
NCT03867435
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
NCT04025554
Modulating the Hippocampal and Striatal Memory Networks With rTMS
NCT03994120
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
NCT02437110
Exploring the Relationship Between Brain Asymmetry and Attention
NCT03789201
Large-Scale Online Studies of Early Motor Skill Learning
NCT03733080
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
NCT03493932
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
NCT03366129
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
NCT03239899
Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in People With Functional Movement Disorders
NCT03263013
Pathophysiology of Focal Hand Dystonia
NCT03223623
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
NCT03263000
Chart Review: Central Motor Conduction Time in Neurological Disorders
NCT03300856
Measuring the Latency Connectome in the Central Nervous Systems Using Neuroimaging and Neurophysiological Techniques
NCT03223636
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
NCT03104725
Loss of Depotentiation in Focal Dystonia
NCT03206112
Clinical and Physiological Studies of Tremor Syndromes
NCT03027310
Neurophysiologic Study of Patient With Essential Tremor and Dystonic Tremor
NCT03041714
Functional Connectivity as a Biomarker of rTMS
NCT03050801
Neurophysiology of Surround Inhibition in the Human Motor Cortex
NCT03018262
Cholinergic Receptor Imaging in Dystonia
NCT02689466
Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
NCT02859428
Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation
NCT02911129
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
NCT02669212
Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells
NCT02694783
In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
NCT02511028
Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing
NCT02504905
Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection
NCT02527460
Natural History of Multiple Sclerosis and Its Mimickers
NCT02504840
Oral Guanabenz for Multiple Sclerosis
NCT02423083
Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function
NCT02408900
Neural Basis of Decision-Making Deficits in Traumatic Brain Injury
NCT02169310
Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
NCT02124057
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 78 |
| Phase 3 | 11 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline
48 recruiting of 567 indexed (8% open); 467 completed (82%).
Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).
Top condition: Healthy (23 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide
Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 567 trials (± recruiting share)
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Jewish Health · 8% recruiting · 83 trials
- ACADIA Pharmaceuticals · 9% recruiting · 35 trials
- Texas Tech University Health Sciences Center, El Paso · 9% recruiting · 35 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
Related
What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page
567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.
- 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets.Report a data error.